{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"}],"units":"Participants"}],"description":"NCI CTCAE version 3.0 will be used to assess adverse events. The number of participants experiencing adverse events and the number of adverse events per patient will be documented through the course of study.","groups":[{"description":"All participants enrolled.","id":"OG000","title":"All Patients"}],"paramType":"NUMBER","populationDescription":"All participants experienced at least 1 adverse event (100% of the patient population; 11/11 participants)","reportingStatus":"POSTED","timeFrame":"To 30 days after end of treatment or until full resolution.","title":"Number of Participants With Adverse Events","type":"SECONDARY","unitOfMeasure":"participants experiencing adverse events"}